Knight Cancer Translational Oncology Program

Medicine & Life Sciences

1. Neoplasms 100%
2. Prostatic Neoplasms 84%
3. Therapeutics 73%
4. Survival 71%
5. Gastrointestinal Stromal Tumors 53%
6. Acute Myeloid Leukemia 52%
7. Mutation 46%
8. Cell Transplantation 45%
9. Free Tissue Flaps 42%
10. Castration 41%
11. Progression-Free Survival 38%
12. Prostatectomy 37%
13. Drug Therapy 37%
14. Recurrence 37%
15. Neoplasm Metastasis 36%
16. Cytomegalovirus 33%
17. Transplants 32%
18. tisagenlecleucel 32%
19. Clinical Trials 32%
20. Neck 30%
21. Protein-Tyrosine Kinases 30%
22. Allogeneic Cells 29%
23. Safety 28%
24. Leukemia 28%
25. Head 28%
26. Imatinib Mesylate 26%
27. Mortality 26%
28. Melanoma 26%
29. Radiotherapy 26%
30. T-Lymphocytes 25%
31. Pyoderma Gangrenosum 24%
32. Neuroendocrine Tumors 24%
33. Precursor Cell Lymphoblastic Leukemia-Lymphoma 23%
34. Colorectal Neoplasms 23%
35. Radiation Oncologists 23%
36. Multiple Myeloma 22%
37. Graft vs Host Disease 22%
38. Pediatrics 22%
39. Databases 21%
40. Confidence Intervals 21%
41. B-Cell Lymphoma 20%
42. Proteogenomics 20%
43. Genes 20%
44. Pharmaceutical Preparations 20%
45. Placebos 20%
46. Phosphotransferases 20%
47. Thrombosis 18%
48. Prostate-Specific Antigen 18%
49. Renal Cell Carcinoma 18%
50. Hematopoietic Stem Cells 18%
51. Bone Marrow 18%
52. Hematopoietic Stem Cell Transplantation 18%
53. Biomarkers 17%
54. Lymphoma, Large B-Cell, Diffuse 17%
55. Genome 17%
56. Immunotherapy 17%
57. Sunitinib 17%
58. Biopsy 17%
59. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17%
60. Breast Neoplasms 17%
61. Radiation Oncology 17%
62. Lymphoma 17%
63. Ferrosoferric Oxide 16%
64. Transplantation 16%
65. Hematologic Neoplasms 16%
66. Chimeric Antigen Receptors 15%
67. venetoclax 15%
68. GC 1 compound 15%
69. Prostate 15%
70. Cancer Care Facilities 15%
71. Quality of Life 15%
72. MDV 3100 15%
73. Veterans 14%
74. Medulloblastoma 14%
75. B-Cell Chronic Lymphocytic Leukemia 14%
76. PCI 32765 14%
77. Androgens 14%
78. Non-Hodgkin's Lymphoma 13%
79. Stem Cell Transplantation 13%
80. Randomized Controlled Trials 13%
81. Central Nervous System 13%
82. Magnetic Resonance Imaging 13%
83. Tissue Donors 13%
84. pembrolizumab 13%
85. Sarcoma 13%
86. Standard of Care 13%
87. Incidence 13%
88. Radiation 12%
89. Adenocarcinoma 12%
90. apalutamide 12%
91. Coronavirus 12%
92. Multicenter Studies 12%
93. regorafenib 12%
94. B-Lymphocytes 12%
95. Glioblastoma 11%
96. Infections 11%
97. daratumumab 11%
98. Vaccines 11%
99. Hemorrhage 11%
100. Myelodysplastic Syndromes 11%